Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage ...

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. Sluggish growth ...

President Donald Trump announces an agreement with drugmakers Novo Nordisk and Eli Lilly to lower the cost of their GLP-1 ...

President Trump promised to lower the cost of Ozempic. Mark Cuban says he's working from the same playbook as Cost Plus, ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on ...

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Experimental pill versions of GLP-1 weight loss drugs by Novo Nordisk and Eli Lilly will receive FDA priority review. Read ...

The Trump administration’s new TrumpRx deal with Eli Lilly and Novo Nordisk will slash GLP-1 drug prices, including Ozempic, ...